[BRAF mutation detection in metastatic melanoma].
Institut für Pathologie, Charité, Berlin, 10117, Berlin, Deutschland.
M
M
Dietel
A
A
Enk
A
A
Lehmann
J
J
Bauer
C
C
Garbe
U
U
Kellner
T
T
Kirchner
A
A
Jung
H
H
Kreipe
S
S
Merkelbach-Bruse
R
R
Büttner
J
J
Rüschoff
W
W
Schlake
P
P
Schirmacher
R
R
Penzel
R
R
Stadler
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D003131:Combined Modality Therapy; D004252:DNA Mutational Analysis; D005858:Germany; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis / Q000473:pathology; D008545:Melanoma / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology / Q000556:secondary*; D058990:Molecular Targeted Therapy; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors / Q000235:genetics*; D011786:Quality Control; D016032:Randomized Controlled Trials as Topic; D060888:Real-Time Polymerase Chain Reaction; D012878:Skin Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use; D000077484:Vemurafenib
D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf